As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Raltegravir tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency ...

German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Tuesday positive data from global KOMET Phase III trial, in which Koselugo ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Daiichi showed the mechanism can work in TGCT years ago, publishing phase 3 data in 2018 and winning FDA approval for Turalio ...

The trial was funded by by a SU2C Catalyst® grant and was supported by Merck’s (known as MSD outside the United States and ...

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...